Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sten Stovall

London, UK
Sten Stovall is a London-based editor and writer with 40 years of experience in the field of journalism, including more than 20 years with Reuters and eight years with The Wall Street Journal/Dow Jones Newswires. He also has wide radio and television reporting experience and a solid network of contacts in the biopharma world. Sten is part of our team of specialist reporters, generating insightful features and analysis about R&D, product development, regulatory issues and industry trends for publications such as "The Pink Sheet", Scrip and IN VIVO.
Advertisement
Set Alert for Articles By Sten Stovall

Latest From Sten Stovall

Narasimhan Promises To Improve Novartis' Image As Top Lawyer Exits

Novartis' top lawyer is taking responsibility for the controversial contract with Essential Consultants and stepping down, amid pledges by the company to polish its tarnished image.

Leadership Business Strategies

Kiadis Poised To Launch Lead Product ATIR101 In 2019

Launch approval of Netherlands-based Kiadis Pharma's lead asset ATIR101 looks likely in Europe by early-2019 for safer, more effective bone marrow transplants. US approval will take longer.

Approvals Business Strategies

Perrigo Generic Of Teva's ProAir Stunned By Another FDA CRL

Perrigo has got another Complete Response Letter on its generic version of Teva's ProAir, the company’s fourth to date, prompting a cut in its 2018 EPS guidance.

Commercial Companies

Bavarian Nordic CEO 'Seeking Big Pharma partner' For RSV Vaccine Program

Phase II trials of Bavarian Nordic’s MVA-BN RSV prophylactic vaccine suggest it boosts memory responses against RSV in patients with a poor underlying immunity. Phase III trials may begin in 2020.

Analysis Clinical Trials

Bavarian Nordic CEO Hopes Chordoma Vaccine Can Be Launched By Mid-2020

Danish vaccine specialist's BN-Brachyury has been granted orphan drug designation by the FDA for treating chordoma.

Rare Diseases Business Strategies

Sarepta Will Challenge Expected No From EMA On Exondys 51

Sarepta is expecting the European Medicines Agency to recommend against EU approval of its Duchenne muscular dystrophy treatment eteplirsen. Persuading the agency to change its mind during the appeal will be an uphill task for the company.

Drug Review Business Strategies
See All
Advertisement
UsernamePublicRestriction

Register